Supernus Pharmaceuticals (SUPN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/28/21
Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHDGlobeNewsWire • 04/02/21
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/28/21
Top-Rated Stocks: Supernus Pharmaceuticals Sees Composite Rating Climb To 96Investors Business Daily • 02/25/21
Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDAGlobeNewsWire • 02/22/21
Supernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric PatientsGlobeNewsWire • 02/08/21